Although the Council will not have any financial consequences, unless otherwise stated, its institutions would provide support and facilitate research and development. | Photo Credit: Getty Images/Istockphoto
The Indian Council for Medical Research (ICMR), Delhi, invited an expression of interest (EOI) from eligible organizations, companies and manufacturers to carry out “transfer of technology” to commercialize “recombinant chimeric multi -stage vaccines to malaria (ADFALCIVAX) head and in the head of humanity and minimizing the plasmodium and on the surface. The aim is to facilitate the commercialization of this vaccine to prevent and minimize the transmission of malaria and the EOI is open until 17 August.
The Council noted that it would provide technical support through their team of experienced scientists in the planning of the study, product development, study protocol development, data results/analysis, evaluation of results, safety and efficacy, product improvement, etc.
In addition, even if the Council will not have any financial consequences, unless otherwise stated, its institutions would provide support and facilitate research and development (R&D)/clinical studies of new technologies/products in India through their associated companies/institutes, in cooperation with companies/institutions. It would also provide technical support in technology/product development and will also facilitate validation if necessary.
“ICMR-REGional Medical Research Center, Bhubaneswar (ICMR-RMRCBB) is one of the four institutes that led to the development of this technology and has a technical knowledge of the process to produce this recombinant chimeric Chimeric institution with Malaria in Laktococcus Lactis. Institute of ICMR and the National Immunology (NII), New Delhi, Autonomous Research Institute of the Ministry of Biotechnology, ”he added.
Published – July 19, 2025 20:29
